News on sequencing-based testing, NGS gene panels, & diagnostic exomes in genetics, genomics, and molecular diagnostics.
The lab will perform DNA and RNA sequencing as well as well as liquid biopsy analyses to advance precision oncology in New Jersey and the East Coast.
The researchers found that sequencing was accurate and could even detect chromosomal changes missed by cytogenetics at almost a similar price.
The new service, slated for launch in the second half of 2021, will allow Myriad to expand its cancer tumor profiling services.
The Chinese company will use the funds to accelerate the registration and commercialization of its NGS-based products for cancer screening and early detection.
With its liquid biopsy test FDA approved and monitoring and screening offerings poised for launch, the firm is turning its attention to tumor tissue testing.
